Form 4: Immunovant CFO Tiago Girao Reports Stock and Option Grants

Tiago Girao, CFO of Immunovant, Inc., reports the acquisition of restricted stock units and stock options.

Summary

• On May 1, 2025, Tiago Girao, the Chief Financial Officer of Immunovant, Inc., was granted 208,388 restricted stock units (RSUs) and options to purchase 293,505 shares of common stock.
• The RSUs and options were granted under the company's 2019 Equity Incentive Plan.
• Both the RSUs and options vest as to 25% on April 21, 2026, and the remaining balance vests in twelve equal quarterly installments thereafter, contingent upon continuous service to Immunovant.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. It's a neutral-positive event.

Positives

• The grant of RSUs and stock options aligns the CFO's interests with those of the shareholders, incentivizing him to contribute to the company's long-term success.
• The vesting schedule encourages continued service and commitment from the CFO.

Future Outlook

The document does not contain specific forward-looking statements regarding the company's future performance, but the equity grants suggest an expectation of continued service and contribution from the CFO.

Industry Context

Equity grants are a common practice in the biotechnology industry to attract and retain key executives, aligning their interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Equity compensation packages for CFOs in the biotechnology industry typically include a mix of stock options and restricted stock units, with vesting schedules designed to incentivize long-term performance.
• The specific amounts and vesting terms vary depending on the company's size, stage of development, and the individual's experience and responsibilities.
• Comparable companies in the biotechnology sector, such as argenx and UCB, also utilize equity grants as a key component of executive compensation.

Stakeholder Impact

• Shareholders may view the equity grants positively as they align management's interests with the company's long-term success.
• Employees may see the grants as a sign of the company's commitment to its leadership team.

Key Dates

Keywords

Immunovant, Tiago Girao, CFO, restricted stock units, stock options, equity incentive plan, Form 4, IMVT, vesting